AZD9668: Pharmacological characterisation of a novel oral inhibitor of neutrophil elastase (NE)
A. Sanfridson, T. Ottosson, K. Ekholm, M. Gränse, V. Kozma, H. Falk Hakansson, H. Lal, T. Stevens, C. Jungar (Lund, Sweden)
Source: Annual Congress 2010 - Pre-clinical models of airways disease
Session: Pre-clinical models of airways disease
Session type: Oral Presentation
Number: 5150
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Sanfridson, T. Ottosson, K. Ekholm, M. Gränse, V. Kozma, H. Falk Hakansson, H. Lal, T. Stevens, C. Jungar (Lund, Sweden). AZD9668: Pharmacological characterisation of a novel oral inhibitor of neutrophil elastase (NE). Eur Respir J 2010; 36: Suppl. 54, 5150
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Pharmacological characterization of CHI25243, a novel potent inhaled inhibitor of neutrophil elastase Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models Year: 2016
Efficacy and safety of AZD9668, an oral neutrophil elastase inhibitor, in idiopathic bronchiectasis Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease Year: 2010
In vitro and in vivo characterisation of the novel neutrophil elastase inhibitor BI 1323495 Source: Virtual Congress 2020 – Scientific advances in airway pharmacology Year: 2020
The selective phosphodiesterase 4 inhibitor, cilomilast, inhibits interleukin-8-induced pulmonary neutrophil accumulation in the rabbit Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001
LSC Abstract – A functional variant of secretory leukocyte protease inhibitor (SLPI) with improved anti-inflammatory activity against pulmonary infection Source: International Congress 2015 – Immunomodulation: basic science and clinical aspects Year: 2015
In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
Suppressive effect of novel phosphodiesterase4 (PDE4) inhibitor ONO-6126 on TNF-α release was increased after repeated oral administration in healthy Japanese subjects Source: Annual Congress 2003 - Novel drugs under development for the treatment of respiratory diseases Year: 2003
A functional variant of secretory leukocyte protease inhibitor (SLPI) with improved anti-inflammatory activity against pulmonary infection Source: Lung Science Conference 2015 Year: 2015
High oral absolute bioavailability of roflumilast, a new, orally active, once daily PDE4 inhibitor Source: Eur Respir J 2001; 18: Suppl. 33, 20s Year: 2001
Safety, tolerability and pharmacokinetics of AZD9668, an oral neutrophil elastase inhibitor, in healthy subjects and patients with COPD Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Dose-dependent inhibitory effect of Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, on allergen-induced early and late asthmatic reaction Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
The novel selective PDE4 inhibitor roflumilast: early onset of efficacy in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003
Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019
Effect of neutrophil elastase inhibitor (ONO-5046) and gabexate mesilate on acid-induced lung injury in rats Source: Eur Respir J 2006; 28: Suppl. 50, 660s Year: 2006
Safety, immunogenicity and pharmacokinetics (PK) of a 120 mg/kg/week dose of alpha1 -proteinase inhibitor in alpha1 -antitrypsin deficiency Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
The novel elastase inhibitor BAY 85-8501: Bioavailability and Food effect study to evaluate pharmacokinetics of tablet formulations Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Smoking has no effect on the pharmacokinetics of roflumilast, a new, orally active, selective PDE4 inhibitor Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001
Safety, tolerability and pharmacokinetics of a new inhaled once-daily phosphodiesterase (PDE) 4 inhibitor in healthy volunteers Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013
The bronchodilatory and anti-inflammatory effect of MT-810, a novel selective phosphodiesterase-4 (PDE4) inhibitor Source: Eur Respir J 2006; 28: Suppl. 50, 434s Year: 2006
Usefulness of selective neutrophil elastase inhibitor, sivelestat, in ALI patients with SIRS Source: Annual Congress 2012 - How to use technology to provide better critical care Year: 2012